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Abstract
Liver cirrhosis (LC), the end stage of many forms of 
chronic hepatitis of different etiologies is a diffuse 
process characterized by fibrosis and the conversion 
of normal liver architecture into structurally abnormal 
nodules surrounded by annular fibrosis. This chronic 
progressive clinical condition, leads to liver cell failure 
and portal hypertension, which can favour the onset 
of hepatocellular carcinoma. Defining the phase of the 
natural history is crucial for therapeutic choice and 
prognosis. Liver biopsy is currently considered the 
best available standard of reference but it has some 
limits, so alternative tools have been developed to 
substitute liver biopsy when assessing liver fibrosis. 
Serum markers offer a cost-effective alternative to liver 
biopsy being less invasive and theoretically without 
complications. They can be classified into direct 
and indirect markers which may be used alone or in 
combination to produce composite scores. Diagnostic 
imaging includes a number of instruments and 
techniques to estimate liver fibrosis and cirrhosis like 
ultrasound (US), US Doppler, contrast enhanced US and 
Elastography. US could be used for the diagnosis of 
advanced LC while is not able to evaluate progression 
of fibrosis, in this case Elastography is more reliable. 
This review aims to revise the most recent data from 
the literature about non invasive methods useful in 
defining liver fibrosis.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: Liver biopsy is the current best available 
standard of reference to diagnose liver fibrosis, but 
it has several limits. Non-invasive methods to detect 
and follow up liver fibrosis (direct and indirect serum 
markers, ultrasound, ultrasound doppler, contrast 
enhanced ultrasound and Elastography) have been 
extensively studied in the last years but strong 
evidences of their usefulness in the real practice are 
still lacking. This work aims to review the most recent 
literature about the use of these non-invasive markers 
in defining liver fibrosis.
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INTRODUCTION
Liver cirrhosis (LC) represents the end stage of  many 
forms of  chronic hepatitis of  different etiologies and 
with quite variable courses[1-6]. In chronic liver disease 
(CLD), the wound-healing process progresses towards 
fibrosis due to the persistence of  a noxa patogena[7]. 
 The accumulation of  collagen fibers and non-
collagenous components in the extracellular matrix 
(ECM) determines a progressive distortion of  liver 
structure until a clear picture emerges of  LC, defined 
as a diffuse process characterized by fibrosis and the 
conversion of  normal liver architecture into structurally 
abnormal nodules surrounded by annular fibrosis[8]. 
Cirrhosis can be either micro- and macro-nodular. In 
macro-nodular cirrhosis, nodules are greater than 3 mm 
in size[9]. It is a chronic progressive clinical condition, 
leading to liver cell failure and portal hypertension, which 
in turn create a micro-environment that favours the onset 
of  hepatocellular carcinoma (HCC). This new condition 
therefore modifies the natural history of  CLD[2].
Progression towards fibrosis and cirrhosis is a 
heterogeneous process influenced in many ways: by 
etiological or host factors (sex, genetics, immunosuppression, 
race, obesity, etc.) and by treatments. 
Clinically, LC may be divided into two phases: (1) 
compensated; and (2) decompensated[10]. Decompensated 
LC is easily diagnosed as it presents with a series of  
clinical and laboratory signs (ascites, spider naevi, 
encephalopathy, esophageal varices, gastrointestinal 
bleeding, thrombocytopenia, hypoalbuminemia), while 
compensated LC may be difficult to differentiate from 
chronic hepatitis. Again, LC may be divided into two 
forms according to the presence/absence of  portal 
hypertension[10]. Consequently, accurate evaluation of  
the fibrosis stage or of  the appearance of  overt cirrhosis 
is fundamental not only to reach a correct diagnosis 
but also to commence correct treatment or screening 
protocols to permit an early diagnosis of  the frequent 
and fatal complications of  LC, such as esophageal varices, 
HCC, etc.[11-13].
FIBROSIS 
Fibrosis consists of  the accumulation over time of  
collagen and non-collagenous material in the ECM of  
interstitial liver as a consequence of  necro-inflammatory 
phenomena due to various etiological factors (viral, 
alcohol, autoimmune, toxic, etc.).
Tools to estimate liver fibrosis may be invasive, such 
as liver biopsy, or non-invasive, which may be divided 
into serological tests and imaging instruments.
Liver biopsy
In the evaluation of  chronic hepatitis, liver biopsy is 
considered as the “reference standard” to determine both 
the necroinflammatory (grading) and the fibrosis (staging) 
components. 
After the discovery of  hepatitis C virus (HCV) in 1989, 
the old qualitative histological classification of  chronic 
hepatitis, (which codified the terms: chronic persistent, 
chronic aggressive and chronic lobular hepatitis) was 
replaced by semiquantitative and reproducible histological 
scoring systems[14,15]. 
Knodell et al[16] were the first to attribute weighted 
numeric values to lesions, creating a score defined as the 
Histology Activity Index (HAI), which evaluated Grading 
and Staging. Since then, several histological classification 
systems have been proposed to stage fibrosis and grade 
necroinflammation in CHC (Table 1).
The Sheuer, Ishak, METAVIR and other scoring 
systems have been used above all for viral liver diseases, 
while for non-alcoholic fatty liver disease (NAFLD) the 
Brunt score has been used[17-21]. The METAVIR and Ishak 
scores are the ones currently most adopted. METAVIR 
divides fibrosis into 5 stages, progressing from absent 
(F0) to mild (F1), significant (F2), advanced (or severe) 
(F3) fibrosis and cirrhosis (F4). The Ishak score is more 
detailed, dividing the disease evolution process into 
six stages. However, although liver biopsy is currently 
considered the gold standard for determining the stage 
of  fibrosis, it has some limitations in correctly defining 
liver disease and, above all, in evaluating its prognosis.
Limitations of liver biopsy
Sampling error: It is well known that liver biopsy 
can over- or under-estimate the degree of  liver disease 
progression in 1/3 cases as it samples only a tiny portion 
of  the liver (about 1/50000). The quality of  liver biopsy 
is determined by the length, width, fragmentation and 
number of  complete portal tracts. A small sample size 
may be inadequate for staging fibrosis, especially in 
pathologies in which histological damage is not uniformly 
distributed[22,23] and cirrhosis can go undetected on a 
single passage in 10%-30% of  cases[24]. For this reason 
Scheuer[24] suggested that “bigger is better”. In the 
literature, the work of  Colleredo clearly demonstrates this 
limitation, and introduces the concept of  a “minimum 
number of  complete portal tracts” necessary for a 
correct diagnosis[25]. However, although the American 
Association for the Study of  Liver Diseases has 
recommended a biopsy sample of  at least 20-30 mm in 
length and containing at least 11 complete portal tracts[26], 
this recommendation is not always followed[27]. 
Inter-observer variability: Despite the introduction of  
the HAI score, inter-observer variability is a reality among 
hepatopathologists, reaching 20% when categorizing the 
degree of  fibrosis[21,28].
Invasiveness: Although quite safe, liver biopsy may lead 
to some moderate (20%) or severe (0.5%) complications 
and mortality (0.03%)[29,30].
 
Dynamic process of  fibrosis: One of  the main 
limitations of  liver biopsy is that fibrosis is a dynamic 
process, thus making this tool of  little use for estimating 
the evolution of  fibrosis and the effect of  therapeutic 
agents on it over time.
Staging cirrhosis: Even when histology shows a 
picture of  cirrhosis, liver biopsy is of  no help in staging 
cirrhosis, and other tools (Hepatic venous pressure 
gradient-HVPG- or esophago-gastroduodenoscopy) are 
necessary to determine the presence and degree of  portal 
hypertension. 
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As liver fibrosis implies morphological damage, liver 
biopsy has become the natural gold standard for staging 
the disease. However, because of  the above-mentioned 
limitations, some authors believe that liver biopsy should 
rather be considered the best available standard of  
reference[31]. For this reason, alternative tools have been 
developed to substitute liver biopsy when assessing liver 
fibrosis. 
Serological test data
Serum markers: Serum markers of  liver fibrosis 
generally offer a cost-effective alternative to liver 
biopsy, they are less invasive and theoretically without 
complications. Thanks to these features they could 
therefore be performed repeatedly and used in 
monitoring the fibrotic process dynamically, for example 
in clinical practice, to follow up the efficacy of  an 
antiviral-therapy in the regression of  fibrosis.
Serum markers of  liver fibrosis can be classified into 
two kinds: (1) direct markers: molecules which derive 
directly from the ECM or are produced by activated 
hepatic stellate cells (HSC), such as hyaluronic acid; 
and (2) indirect markers: molecules produced by the 
liver parenchyma following chronic damage either of  
hepatocyte (AST) or cholangiocyte (GGT) origin, or 
those which indicate compromised hepatic synthesis 
(bilirubin, INR) or the presence of  portal hypertension 
(platelets, gamma globulin). Direct and indirect markers 
may be used alone or in combination to produce 
composite scores which can be relatively simple to 
calculate or based on complex formulas. 
Direct serum markers
Hyaluronan: Hyaluronan (formerly termed hyaluronic 
acid) is an anionic, non-sulfated glycosaminoglycan widely 
distributed throughout connective, epithelial, and neural 
tissues. It is currently considered one of  the best direct 
markers of  fibrosis, having sensitivity and specificity 
values of  86%-100% and 88% respectively in NAFLD[32] 
and in fibrosis related to other etiologies[33]. Moreover, at 
a cut-off  concentration of  60 μg/L it has been shown 
to have a high negative predictive value (98%-100%), 
which is significantly higher than the positive predictive 
value (61%). This is probably because its synthesis is 
stimulated in the activated HSC[34], then it is secreted into 
the sinusoidal bloodstream where it normally has a short 
half-life, but this is prolonged in disease conditions[34]. 
Consequently, its main usefulness could be for ruling out 
advanced fibrosis and cirrhosis. 
Procollagen Type Ⅰ Carboxy terminal peptide 
and Procollagen type Ⅲ amino-terminal peptide: 
A procollagen peptide contains an additional peptide 
sequence at its amino- and carboxy-terminal end, known 
as the propeptide. Collagen types Ⅰ, Ⅱ, Ⅲ, Ⅳ and Ⅴ are 
synthesized as precursor molecules called procollagens. 
These propeptides are cleaved from the collagen 
molecule during its secretion, after which the collagens 
polymerize into extracellular collagen fibrils. The amount 
of  free propeptides thus directly correlates with collagen 
molecule synthesis. Procollagen Type Ⅰ C-peptide (PICP) 
has been extensively referenced in studies correlating 
collagen levels and health disorders such as liver fibrosis. 
For example, PICP levels have been shown to be normal 
in patients with mild chronic hepatitis C and elevated in 
50% of  patients with moderately advanced or advanced 
chronic hepatitis C, including patients with LC[35].
However, among the several pro-collagen and 
collagen fragments proposed as biomarkers[36] only the 
aminoterminal propeptide of  type Ⅲ pro-collagen (P
ⅢNP) has had a limited clinical application[37], with 
sensitivity and specificity values varying considerably 
(around 76%-78% and 71%-81%, respectively). These 
specificity values are unconvincing because PⅢNP is 
not only specific for liver fibrosis as it is also elevated 
in lung fibrosis, chronic pancreatitis and rheumatologic 
diseases[38].
Metalloproteinases: Matrix metalloproteinases (MMPs) 
are zinc-dependent endopeptidases which are capable 
of  degrading all kinds of  extracellular matrix proteins, 
but can also process a number of  bioactive molecules. 
The three most commonly studied human MMPs are: 
MMP-2 (gelatinase-A), MMP-3 (stromelysin) and MMP-9 
(gelatinase-B). MMP-2 circulating levels studied in 
patients with chronic hepatitis C were not significantly 
related to the degree of  liver fibrosis[39]. In another study, 
serum MMP-9 levels were shown to decrease during the 
progression of  chronic hepatitis to cirrhosis, with the 
lowest level in the cirrhosis group[40].
Tissue inhibitors of  matrix metalloproteinases: 
MMPs are inhibited by specific endogenous tissue 
inhibitors of  matrix metalloproteinases (TIMPs), which 
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Table 1  Histology activity index for staging liver fibrosis according to various scores








Marked bridging with 
occasional nodules
Cirrhosis
Knodell et al[16] F0 F1 F1 F3 F3 F4 F4
Scheuer et al[17] F0 F1 F2 F2 F3 F3 F4
IASL[18] F0 F1 F2 F2 F3 F3 F4
Ishak et al[19] F0 F1 F2 F3 F4 F5 F6
METAVIR[20] F0 F1 F1 F2 F3 F4 F4
IASL: International Association for the Study of the Liver. 
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associated with wound healing and virtually all fibrotic 
pathologies. CTGF is thought to cooperate with TGF-β 
to induce sustained fibrosis and to exacerbate extracellular 
matrix production in fibrosis-inducing conditions. In 
a recent study the diagnostic performance of  CTGF 
was assessed by comparing the area under the receiver 
operating characteristic (ROC) curves (AUC) with a panel 
of  fibrosis markers. The correlation coefficient between 
serum CTGF levels and fibrosis stages was 0.689 and 
the AUC of  CTGF was 0.841 (95%CI: 0.762-0.920) in 
distinguishing mild fibrosis from significant fibrosis[45]. 
Values were even better in a previous study where the 
AUCs for fibrosis vs controls and for cirrhosis patients vs 
controls were 0.955 and 0.887, respectively, with 100% 
and 84% sensitivity, respectively, and 89% and 85% 
specificity, respectively[46].
YKL-40: YKL-40,  a lso cal led human car t i lage 
glycoprotein-39 (HC gp-39), is a member of  the 18 
glycosyl hydrolase family. The pattern of  its expression 
in normal and disease states suggests that it could have a 
function in remodeling or facilitating the degradation of  
the extracellular matrix. Elevated YKL-40 concentrations 
have been found in the sera of  liver disease patients. In 
particular, sensitivity and specificity values around 80% 
and an AUC of  0.81 for fibrosis were reported in a study 
on HCV-related chronic hepatitis patients[47], and 88% 
specificity and 51% sensitivity were reported in alcoholic 
liver disease patients[48]. Moreover, the CHI3L1 promoter 
polymorphism -131G > C, which determines YKL-40 
serum levels, was associated with the severity of  HCV-
induced liver fibrosis[49].
Microfibril-associated glycoprotein 4: To identify new 
candidate biomarkers for hepatic fibrosis, a proteomic 
approach of  microdissected cirrhotic septa and liver 
parenchyma cells was performed. In the cirrhotic 
septa, an increase was detected in the expression of  
cell-structure-associated proteins, including human 
microfibril-associated protein 4 (MFAP-4). A subsequent 
quantitative analysis of  MFAP-4 serum levels in a large 
number of  patients showed a high diagnostic accuracy 
for predicting non-diseased liver vs cirrhosis: AUC = 
0.97; for stage 0 vs stage 4 fibrosis: AUC = 0.84; and 
for stages 0 to 3 vs stage 4 fibrosis: AUC = 0.76[50]. This 
consequently represents a novel approach to study new 
markers of  liver fibrosis.
Cytokeratin-18 fragments: Cytokeratin-18 (CK18) is 
an intermediate filament representing about 5% of  total 
protein in various epithelial and parenchymal cells[51]. 
Different caspases induce the apoptosis mechanism via 
the cleavage of  CK 18 in different positions, forming 
CK18 fragments (CK18Fs)[52]. In the study of  Bantel 
et al[53], raised concentrations of  CK18 fragments were 
evident in HCV patients with advanced liver fibrosis. 
Yilmaz et al[54] showed that in NAFLD patients levels of  
M30 antigen (a neoepitope in cytokeratin 18) and M65 
comprise a family of  four protease inhibitors: TIMP1, 
TIMP2, TIMP3 and TIMP4. TIMP-dependent inhibition 
of  ECM degradation may promote liver fibrosis, and an 
elevation in TIMP levels has been described in chronic 
liver diseases. In detail, in a group of  patients with 
chronic hepatitis C plasma TIMP-1 levels were shown 
to significantly correlate with histological activity index, 
portal inflammation and periportal and focal necrosis. 
Moreover, plasma TIMP-2 levels significantly correlated 
with fibrosis and confluent necrosis. Using ROC analysis 
both TIMP-1 and TIMP-2 had a significant diagnostic 
ability in detecting advanced liver disease (AUC = 0.73 
for both, P = 0.015 and 0.036 respectively), while normal 
plasma TIMP-1 excluded advanced liver disease[39]. Badra 
et al[40] also found a positive correlation between TIMP-1 
levels and degree of  fibrosis when studying patients with 
chronic hepatitis and LC.
Laminin: Laminins are a major ECM protein component 
of  the basal lamina. In general, they are heterotrimeric 
glycoproteins with binding regions for collagen, integrins, 
cellular domains and proteoglycans. In the liver they are 
synthesized by Ito cells and for this reason considered 
a marker of  fibrogenesis. The concentration of  laminin 
has been reported to be correlated with portal venous 
pressure, thus being a potentially useful biochemical 
marker of  portal hypertension. In detail, at a cut-off  
concentration of  1.45 U/mL, sensitivity was 0.87, 
specificity 0.74, diagnostic efficiency 0.81 and positive 
and negative predictive values at the same cut-off  were 
0.77 and 0.85, respectively[41]. In a subsequent study, an 
increased concentration of  laminin was described in a 
group of  cirrhotic patients and significant differences in 
laminin concentrations were found between the various 
Child’s grades and between patients and controls[42].
Transforming growth factor-beta1: Transforming 
growth factor beta 1 (TGF-β1) is a polypeptide member 
of  the transforming growth factor beta superfamily of  
cytokines. It is a secreted protein that performs many 
cellular functions and has been identified as a pro-
fibrogenic cytokine. For this reason, TGF-β1 blood 
concentrations have been studied as markers of  liver 
fibrosis. In a study on the prediction of  progressive 
liver fibrosis in hepatitis C infection a close correlation 
was found between TGF-β serum levels and the rate 
of  fibrosis progression. Patients with no progression 
of  fibrosis had significantly lower TGF-β serum levels 
than patients with progressive disease, and a TGF-β 
level below 75 ng/mL was predictive of  stable disease[43]. 
Furthermore, in a previous study on 88 patients with 
chronic HCV, a correlation was found between TGF-β 
levels and severity of  fibrosis[44].
Connective tissue growth factor: Connective tissue 
growth factor (CTGF), also known as CCN2, is a 
matricellular protein of  the CCN family of  extracellular 
matrix-associated heparin-binding proteins and it is 
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(the cytosolic pool of  CK18) distinguished between 
advanced fibrosis and early-stage fibrosis, with 64% and 
70% sensitivity, and 77% and 71% specificity, respectively.
Indirect serum markers: Several scores have been 
proposed to attempt to overcome the need for liver 
biopsy in diagnosing and monitoring the fibrotic process 
in chronic liver diseases. Most of  the literature data, 
however, have been obtained in mainly HCV-infected 
patient case series. Table 2 summarizes the principal 
scoring systems, taking into account the parameters used 
in calculating the scores, etiology of  liver disease and 
sensitivity and specificity values of  the tests.
The first diagnostic index was proposed by Williams 
et al[58], who suggested that an AST/ALT ratio of  > 1.0 
in a patient with non-alcoholic liver disease should be 
related to the presence of  cirrhosis. Poynard et al[55] then 
proposed a simple score combining age and platelet 
count, referred to as AP, which had 93% specificity 
and 52% sensitivity in identifying histological disease in 
hepatitis C-infected patients. In the same year, a paper 
by Bonacini et al[60] assessed the utility of  a modified 
three-parameter cirrhosis discriminant score (CDS) for 
diagnosing advanced fibrosis or cirrhosis in patients with 
evidence of  chronic hepatitis C, taking into account three 
laboratory parameters (platelets, ALT/AST ratio and 
PT). It showed a positive correlation between the CDS 
and histological fibrosis score which was 46% sensitive 
and 98% specific for the diagnosis of  histological fibrosis 
scores of  3 or 4. 
Since then, a great number of  papers have been 
published with novel scores whose sensitivity and 
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Table 2  Principal scoring systems taking into account the parameters used in calculating the scores, etiology of liver disease and 
sensitivity and specificity values of the tests
Test Parameters Etiology Sensitivity Specificity
Age-platelet index (AP)[55] Age, platelet count HCV 52% 93%
APRI[56] AST/platelet count HCV 57% 93%
ASPRI[57] Age, spleen diameter, platelet count HBV 75% 90%
AST/ALT ratio[58] Aspartate aminotransferase, alanine aminotransferase HBV 51% 71%
BARD score[59] BMI, AST/ALT ratio, diabetes NAFLD 62% 66%
Bonacini-index (Cirrhosis discriminant score - CDS)[60] ALT/AST ratio, INR, platelet count HCV 46% 98%
ELF and simplified ELF index[61] Age, Hyaluronic acid, N-terminal propeptide of type Ⅱ 
collagen, and TIMP-1 levels
Mixed 90% 69%
FIB-4[62] Platelet count, AST, ALT, age HIV/HCV 65% 97%
Fibro-α score[63] Platelet count, AST, ALT, α-fetoprotein level HCV 90% 57%
Fibroindex[64] Platelet count, AST, γ-globulin HCV 35% 97%








Fibrometer NAFLD[66] Glucose, AST, ALT, ferritin, platelet count, body weight, age NAFLD 79% 96%
Fibronectin discriminant score[67] Platelet count, AST, Albumin and fibronectin levels HCV 87% 75%
FibroQ[68] Age, platelet count, AST, ALT, Prothrombin index HBV/HCV 79% 71%
Fibrosis-cirrhosis index[69] Platelet count, Alkaline phosphatase, bilirubin, albumin levels HCV 86% 80%
Fibrosis index[70] Platelet count, Albumin level HCV 67% 97%
Fibrosis probability index
(Sud index)[71]
Age, AST, Total cholesterol level, insulin resistance and 
alcohol intake
HCV 73% 74%
Fibrosis Routine Test[72] Age, platelet count, AST, α-fetoprotein and albumin levels HCV 83% 73%
FibroSpect Ⅱ[73] hyaluronan, TIMP-1,α2-macroglobulin HCV 76% 73%
Fibrotest[74] Haptoglobin, α2-macroglobulin, apolipoprotein A1, γGT, 
bilirubin, gender
HCV 75% 85%
Forns-index[75] Age, platelet count, γGT, cholesterol HCV 30% 95%
Globulin-albumin ratio[76] Globulin and albumin levels HCV 43% 98%
GUCI[77] Platelet count, AST, Prothrombin index HCV 80% 78%
HALT-C model[78] Platelet count, TIMP-1 and hyaluronic acid levels HCV 71% 80%
Hepascore[79] Bilirubin, γGT, hyaluronan, α2-macroglobulin, age, gender HCV 84% 71%
King’s score[80] Age, platelet count, AST, INR HCV 86% 80%
Lok index[81] Platelet count, AST, ALT, INR HCV 68% 72%
MP3 score[82] MMP-1 and PⅢP levels HCV 60% 92%
NAFLD fibrosis score[83] Age, hyperglycemia, BMI, platelet count, albumin, AST/ALT 
ratio (dual cut-offs)
NAFLD 77% 96%
Pohl index[84] Platelet count, AST, ALT HCV 41% 99%
Sabadell NIHCED index[85] Age, platelet count, AST, ALT, Prothrombin time, right hepatic 
lobe atrophy, splenomegaly, and caudate lobe hypertrophy
HCV 80% 96%
Significant fibrosis index[86] Haptoglobin, α2-macroglobulin, TIMP-1, MMP-2, and GGT 
levels
HBV/HCV 71% 80%
VITRO score[87] vWF-Ag, platelet count HCV 83% 79%
Zeng index[88] Age, α2-Macroglobulin, GGT, and hyaluronic acid levels HBV 40% 90%
Soresi M et al . Diagnosis of liver cirrhosis
AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; BMI: Body mass index; ELF: Enhanced liver fibrosis; NAFLD: Non-alcoholic fatty liver 
disease; TIMP: Tissue inhibitors of metalloproteinases; MMP-1: Matrix metalloproteinase-1; GGT: γ-glutamyl transferase.
specificity values were announced as being better than 
the previous ones, but actually none have been adopted 
in clinical practice. The principal ones are Fibrotest[75], 
Forns[76], APRI[56] and FIB-4[62]. 
As regards the Fibrotest, its authors concluded that 
a combination of  simple serum tests could be used to 
reduce the need for liver biopsy, the most informative 
markers being alpha2-macroglobulin, alpha2-globulin 
(or haptoglobin), gamma globulin, apolipoprotein A1, 
gamma glutamyltranspeptidase and total bilirubin. With 
the best index, a high negative predictive value (100% 
certainty of  absence of  F2, F3, or F4) was obtained for 
scores ranging from zero to 0.10 (12% of  all patients), 
and a high positive predictive value (> 90% certainty of  
presence of  F2, F3, or F4) for scores ranging from 0.60 
to 1.00 (34% of  all patients)[75]. Subsequently, Forns et 
al[75] constructed a model and a score system combining 
age, GGT, cholesterol and platelet count which aimed to 
identify patients without significant liver fibrosis. Using 
the best cut-off  score, the presence of  significant fibrosis 
could be excluded with high accuracy (negative predictive 
value of  96%) in 36% of  the patients. 
The APRI score was then developed to amplify the 
opposing effects of  liver fibrosis on AST and platelet 
count. Using optimized cut-off  values, the authors 
showed that significant fibrosis could be accurately 
predicted in 51% and cirrhosis in 81% of  patients with 
chronic HCV infection[56]. 
The FIB-4 index was developed to predict liver 
fibrosis in patients with HIV/HCV coinfection. It was 
calculated taking into account simple parameters such 
as age, AST and ALT levels and PLT count, and the 
authors proved that 87% of  the 198 patients with FIB-4 
values outside the cut off-values would be correctly 
classified, thus liver biopsy could be avoided in 71% of  
the validation group[62].
IMAGING INSTRUMENTS
Diagnostic imaging includes a number of  instruments 
and techniques to estimate liver fibrosis and cirrhosis.
Ultrasound
Ultrasound (US) is routinely used in the diagnosis and 
monitoring of  subjects with chronic liver disease. It is 
inexpensive, non-invasive, readily available and acceptable 
to patients. This tool is also recommended by various 
international guidelines for evaluating the large spectrum 
of  CLD. It provides useful data on the morphologic 
changes taking place in the liver, as well as on CLD 
complications (such as portal hypertension), and it also 
enables the early detection of  HCC[12,13,89]. Indeed, its 
performance in screening programs has changed the 
clinical and laboratory presentation of  HCC in the new 
millennium[90]. 
The introduction of  US has made the liver a very 
easy organ to study and during the last few decades 
ultrasound imaging, which ranges from gray-scale to real 
time gray-scale US, color-Doppler and, more recently, 
contrast-enhanced US (CEUS), has provided further, 
important information on the diagnosis and progression 
of  CLD[90-92].
Gray-scale US: Gray-scale US (B-Mode) imaging of  a 
given organ includes an evaluation of  size, echo-pattern 
and surface.
Size: Classically, in LC there is an atrophy of  the right 
lobe associated with hypertrophy of  the left lobe, 
while the caudate lobe and lateral segment of  the left 
lobe occupy a larger proportion of  the liver volume. 
Hypertrophy of  the caudate lobe is a highly specific 
finding of  LC (Figure 1), while in the advanced phase 
atrophy is complete. Various studies have reported that 
this asymmetry can be clearly seen at US, in the raised 
volume of  the caudate lobe alone or in the increased ratio 
between the transverse diameter of  the caudate lobe and 
the transverse diameter of  the right lobe. Values > 0.65 
are abnormal. This ratio, however, indicates an advanced 
LC with a good specificity (95%), but a low sensitivity 
(43%), therefore, it is inaccurate for the early diagnosis of  
LC[93].
Echo-patterns: The definition of  echo-patterns in 
diffuse liver diseases has been debated in the literature, 
studies often reporting contrasting results. The echo-
pattern of  cirrhosis has been defined as a coarse pattern, 
which is characterized by ‘‘pinhead’’ echoes which are 
coarse and not homogeneously distributed, without 
posterior beam attenuation (Figure 1)[94,95]. Sensitivity and 
specificity are estimated as 57% and 88%, respectively[96]. 
This sub-optimal diagnostic reliability is due to 
different factors: (1) the same pattern may also be 
found in CLD without cirrhosis and it may be lacking in 
cirrhosis, especially in the early phase; (2) inter-observer 
variability: according to some authors, inter-observer 
agreement (assessed by the kappa value k) in defining the 
echo-pattern of  diffuse liver disease is insufficient (around 
0.4)[97,98]; and (3) high echogenicity: the coarse pattern 
increases liver echogenicity, causing some difficulty in 
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Figure 1  A longitudinal epigastric scan shows the left lobe of the liver 
with irregularity of liver surface, lobo caudate hypertrophy and coarse 
pattern. 
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differentiating between cirrhosis and steatosis. The many 
papers published on this issue have reported that the 
presence of  attenuation beam and of  focal steatosis, 
which are lacking in cirrhosis, helps to distinguish 
between the two forms[94,97,99,100]. 
The mechanism of  attenuation depends on physical 
phenomena defined as: scatter, absorption and refraction. 
These are enhanced by the large interfaces of  lipidic 
drops typical of  steatosis, while the cirrhotic liver, which 
has few interfaces, does not favour these phenomena[101]. 
However, the attenuation beam and focal steatosis are not 
always found in steatosis and many forms of  NAFLD 
present both fatty and fibrotic liver during their course, 
thus making differentiation difficult[102].
Liver surface: Micro- or macro-nodularity in LC are seen 
at US as liver surface irregularities. In the micronodular 
forms the liver presents only a superficial irregularity, 
which is much more evident in macronodular LC (Figure 
1). This is considered one of  the most sensitive and 
more reproducible US signs (k of  agreement range 0.77- 
0.9)[103,104]. 
 Gaiani et al[105] reported 82% sensitivity and 79% 
specificity for this sign when associated with reduction in 
portal velocity. Further, Colli et al[106] and Iacobellis et al[107] 
reported a sensitivity of  54% and 46%, and a specificity 
of  93% and 95% for surface irregularity alone. Iacobellis 
reported a sensitivity of  90% and specificity of  83% 
when combining surface irregularity with a platelet count 
< 140000/mmc. To confirm that the association between 
US and serum data improves LC diagnosis, Colli et al[104] 
used the model based on the sequential combination of  
the Bonacini score (ALT/AST ratio, platelet count and 
INR) associated with US liver surface characteristics in 
176 patients with chronic HCV infection. They were 
able to define the presence/absence of  severe fibrosis 
or cirrhosis in 67%; only in 33% of  the patients was a 
biopsy required.
Recently, Berzigotti et al[103] compared left lobe liver 
surface irregularity with transient elastography (TE) to 
assess the diagnostic value of  these methods in patients 
with a suspected but not definite diagnosis of  cirrhosis. 
They found that liver surface irregularity evaluation was 
better for LC diagnosis, while TE was preferable to rule it 
out. The combination of  both offered the best diagnostic 
accuracy.
Other gray-scale US findings are useful in the staging 
and follow-up of  LC, but much less so in early diagnosis.
Portal vein dilatation: A diameter greater than 1.2 cm 
has a sensitivity of  less than 50% and a 90% specificity 
for the diagnosis of  portal hypertension[108].
Dilatation and reduction in the respiratory variations 
of  splenic and mesenteric vein diameters have 79.7% 
sensitivity and 100% specificity for the diagnosis of  
portal hypertension[108].
Splenomegaly: Spleen bipolar diameter > 12 cm or 
largest splenic cross-sectional area passing through the 
hilum > 45 cm2 may indicate portal hypertension[92]; 
Berzigotti et al[109] reported that spleen diameter was 
the only US sign showing a significant association with 
clinically significant portal hypertension (hepatic venous 
pressure gradient ≥ 10 mmHg) at univariate analysis. 
However, splenomegaly may be induced by many 
other causes and therefore is not specific for portal 
hypertension.
Ultrasound is also a very useful and reliable method 
in the estimation of  liver fibrosis and portal hypertension 
in patients with hepato-splenic schistosomiasis, especially 
in countries where this infection is endemic. In fact, the 
World Health Organization believes that the diagnosis 
of  liver fibrosis, in developing countries, may reliably 
be based on ultrasound and proposes guidelines for 
schistosomiasis, which are modified for S. japonicum 
infection, in which the parenchymal and periportal 
fibrosis are graded separately[110,111]. The knowledge of  
these guidelines is very useful also in Western countries 
where recent migration flows have brought this disease 
uncommon in the past.
Doppler US
The Doppler US signs for portal hypertension are: (1) 
reduced portal vein blood flow velocity (time-averaged 
mean vel. < 14-16 cm/s2), with sensitivity and specificity 
between 80-88% and 80-96%, respectively[92]; (2) 
portal vein congestion index > 0.08. This parameter[92], 
however, is not used routinely, probably due to its being 
difficult to measure and its lower reproducibility; and (3) 
measurements of  the hepatic arterial Resistive Index are 
less useful[92].
In the course of  LC, the appearance of  clinically 
significant portal hypertension worsens prognosis 
and Doppler US is very useful in evaluating portal 
hypertension. However, it is not sufficient without the 
integration of  gray-scale US and serological and clinical 
data. Furthermore, Doppler US alone is not able to 
predict the presence of  esophageal varices[92]. 
Contrast-enhanced ultrasonography 
CEUS is prevalently used in the study of  liver tumors. 
However, in recent years it has also been used in the 
evaluation of  liver fibrosis[112,113]. The rationale for its 
application stems from the changes in intrahepatic 
microcirculation that occur in chronic liver diseases with 
fibrotic evolution. 
Normally, the blood flows from the portal branches 
to the sinusoids and hepatic veins. In patients with 
severe fibrosis or cirrhosis, there are severe changes 
in the microcirculation (arteriovenous shunting and 
arterialisation of  capillary beds) which lead to a by-
pass of  the sinusoids, with blood passing directly into 
the hepatic veins, and this determines a reduction in 
transit time (hyperdynamic flow). By using CEUS and 
calculating intrahepatic transit time, hyperdynamic flow 
may be estimated. Contrast arrival time and baseline 
and peak intensity in the hepatic artery, portal vein, 
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right hepatic vein and liver parenchyma have been used 
to calculate intrahepatic transit time, hepatic artery to 
hepatic vein transit time (HA-HVTT) and portal vein to 
hepatic vein transit time (PV-HVTT). To diagnose severe 
fibrosis, Staub et al[112] found for a transit time of  under 
13 s, 78.5% of  specificity, 78.9% of  sensitivity, 78.3% of  
positive predictive value, 83.3% of  negative predictive 
value and a 78.8% performance accuracy. Transit time 
was computed as the difference between the arrival 
of  microbubbles in the portal vein and in the hepatic 
vein (PV-HATT). HA-HVTT and PV-HVTT gradually 
shortened with the progression of  liver fibrosis[113]. 
Recently, however, the EFSUMB (European Federation 
of  Societies for Ultrasound in Medicine and Biology) 
considered that its use in staging chronic hepatitis is also 
limited by the substantial overlap between the different 
stages of  fibrosis[92]. 
In conclusion, gray-scale US has an limited sensitivity 
and specificity in LC diagnosis, although diagnostic 
reliability improves when Doppler US or laboratory 
data are added. In fact, the most accurate sign, i.e., liver 
surface irregularity alone, has a 55% sensitivity, while in 
association with platelet count this reaches 90%[107,108]. 
Finally, US is not able to evaluate either the progression 
of  fibrosis or the more advanced stage of  the disease (F3).
Elastography
In the last two decades new diagnostic tools have been 
developed which, when supported by ultrasound, 
permit the estimation of  fibrosis. They are based on the 
hypothesis that fibrosis in a given tissue determines a 
reduction in elasticity or an increase in stiffness[114-116].
During the course of  chronic hepatitis, the liver 
becomes more fibrotic and its stiffness therefore increases. 
This may be recorded by transient elastometry (TE), 
which measures the degree of  stiffness using ultrasounds. 
TE is therefore the equivalent of  palpation, and for this 
reason it has been defined “palpation imaging”[114-116].
Two concepts are fundamental for elastography: (1) 
the evaluation of  strain which deforms the tissue (due to 
a force that deforms the tissue) namely static or quasi-
static methods, which are defined as strain imaging 
techniques; and (2) the speed analysis of  a shear wave 
induced by a mechanical vibrator or other techniques, is 
defined as the shear-wave technique[114]. 
The stiffer a tissue is, the higher the propagation 
speed of  US waves will be; their evaluation will allow an 
estimation of  stiffness.
Strain imaging: In this group, the distortions generated 
by compressions created by hand, with a probe, by the 
heartbeat or by arterial pulse on adjacent tissues, are 
measured. 
Strain imaging may measure stiffness as follows: (1) 
qualitative: stiffness is given in the gray or colour scale; 
this is the method used in real-time elastography (RTE); 
and (2) semi-quantitative, based on the ratio strain: two 
regions of  interest (ROIs) are selected: the surface to 
be examined and the adjacent one, which serves as a 
reference. The ratio between the two strains gives a semi-
quantitative measure. 
Shear wave technique: It evaluates the speed of  
propagation of  a shear wave induced by a mechanical 
vibrator or other methods. The greater the hardness of  
a tissue, the greater the speed of  propagation of  the 
ultrasonic waves will be and the greater its stiffness. The 
propagation speed of  the shear wave is expressed in m/s 
or Kilopascals (kPa) (using Young’s modulus)[115]. 
The quantitative measure is more useful in the study 
of  liver stiffness. The stiffer a tissue is, the greater its 
strain.
For liver study there are several elastography 
techniques, the best known are: TE and acoustic radiation 
force impulse (ARFI). 
The proliferation of  all these methods complicates 
the interpretation of  results because they are often not 
equivalent; the cut-off  of  one method, even if  expressed 
in the same unit of  measure is often not comparable with 
another[117]. 
Moreover, all these techniques have some limitations 
in common: (1) liver stiffness is not only determined by 
the degree of  fibrosis, but also by the degree of  necrosis 
and inflammation and is influenced by cholestasis. 
Therefore, stiffness values may be high without being an 
expression of  fibrosis, i.e., in acute hepatitis, during the 
viral flare of  chronic hepatitis, biliary tree obstruction 
etc.[118-120]; (2) measures are less accurate if  there is venous 
insufficiency or when they are performed near the 
hepatic capsule[120,121], and (3) the reference values of  
stiffness may have different cut-offs due to the different 
etiologies of  liver disease[121].
TE
TE (FibroScan TM® EchoSensTM, Paris, France), uses 
an M ultrasound probe (5 MHz) with a dedicated 
vibrating system that produces mechanical waves with a 
low frequency and amplitude (50 MHz). A mechanical 
impulse generates shear waves in the liver which come 
back to the transducer mounted on the end of  the probe, 
which functions as both a generator and receiver; the 
shear wave velocity measured (in meters per second) can 
then be converted into liver stiffness. 
Liver stiffness measurement is proportional to the 
speed of  propagation and is expressed in kiloPascals 
(kPa), in accordance with Young’s modulus. The 
result ranges from 2.5 to 75 kPa. The measurement is 
performed at a depth below the skin surface of  between 
2.5 cm and 7.5 cm. The final value obtained is the mean 
of  ten measurements. The liver sample evaluated is 
around 100 times greater than that of  a liver biopsy[122]. 
Besides the liver stiffness value, another two values are 
given, i.e., the success rate (SR), which corresponds to 
the rate of  the number of  measurements/total number 
of  valid results (corresponding to the number of  
measurements obtained/number impulses applied) and 
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the interquartile range (IQR). The test is not reliable if  
the SR is less than 60% or the IQR is higher than 30%[122] 
(Figure 2A and B).
This tool is the one most frequently applied in 
liver diseases, it is easy to use and only a short training 
period (50 tests) is necessary. However, it has a high 
interobserver variability 0.98 (95%CI: 0.977-0.987), 
but when fibrosis is at the lowest stage (minimal) the 
intra-observer and inter-observer variability is even 
greater[122,124]. The normality threshold in Roulot’s study 
was 5.8 ± 1.54 in men and 5.23 ± 1.59 kPa in women[125].
TE has been largely studied for HCV-associated CLD, 
but in recent years many studies have estimated stiffness 
in HBV-associated liver disease, in co-infected HBV/
HCV patients, as well as in nonalcoholic steatohepatitis 
(NASH) and autoimmune cholestatic liver diseases. 
In most of  these cases TE has been compared to the 
METAVIR score scoring system[20]. All these studies 
have demonstrated that there is no specific cut-off  
to discriminate LC and that it varies according to the 
etiology of  liver disease.
HCV liver diseases: Most studies have been performed 
on HCV liver diseases and different cut-off  values have 
been used by the various authors to define fibrosis 
stages. Recently the European Federation of  Societies for 
Ultrasound in Medicine and Biology (EFSUMB) issued 
guidelines in which values above 6.8-7.6 kPa may indicate 
the presence of  significant fibrosis (F ≥ 2 according 
to METAVIR score) with a high probability, while the 
range 11-13.6 kPa may indicate a cirrhotic stage (F = 4 
according to METAVIR score) (Figure 2B). All these 
studies have shown that TE is able to define the presence 
of  cirrhosis with a good diagnostic reliability, while it is 
less able to define the minor stages of  fibrosis. Meta-
analyses performed to date have indicated that in HCV-
associated CLD sensitivity and specificity in defining a 
stage F ≥ 2 are 78% and 79%, respectively; for an F = 
4 stage sensitivity is 83% and specificity 89%[117,124-129]. 
EASL guidelines indicate that TE can be used to assess 
liver fibrosis in patients with chronic hepatitis C (level of  
recommendation A2)[130].
HBV liver diseases: In chronic hepatitis B many studies 
have indicated that values of  7 kPa parallel an F ≥ 2 
stage and 11 kPa an F4, according to the METAVIR 
score; a recent meta-analysis at these cut-offs estimated 
an Area Under ROC of  0.887 and 0.92, respectively[131-134]. 
In chronic hepatitis B the frequent ALT flares (the 
expression of  necro-inflammatory processes) influence 
stiffness values independently of  fibrosis[122-133]. Further, 
in the guidelines for the management of  chronic HBV 
infection, the EASL advises TE to estimate liver fibrosis 
(level of  recommendation B1 and C2)[135].
HCV/HIV co-infection: Also in HCV/HIV co-infected 
patients the reliability of  FibroScan TMTM is good; de 
Leidighen reported a sensitivity of  100% and specificity of  
83% to define the F4 stage at a cut-off  level of  11.8[136,137].
Alcoholic liver diseases: In patients with chronic alcoholic 
liver diseases, higher cut-off  values indicating cirrhosis 
(19.5 kPa) are reported, with a sensitivity and specificity 
of  85.7% and 84.2%, respectively. However, it has been 
reported recently that stiffness values decrease after 
alcohol withdrawal[138,139].
NAFLD/NASH: The studies on NAFLD and NASH 
are very interesting. This is the most common liver 
disease in the Western world, largely associated to the 
metabolic syndrome[6]; progression to LC is frequent[5] 
and often there are no signs or symptoms. Due to the 
high number of  patients suffering from NAFLD, TE 
could be an ideal tool to monitor these patients and to 
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Figure 2  The stiffness (KPa); the interquartile-range = variability of valid measurements; the Success Rate = Ratio between the number of valid 
measurements/number of measurements in total (A and B). The ratio between the speed of propagation of the wave and the elasticity of the liver parenchyma is 
represented by the slope of the white line (indicated by the white arrows in the elastogram). In panel A subject with normal value of liver stiffness. In panel B patient 
with value of liver stiffness compatible with liver cirrhosis.
Soresi M et al . Diagnosis of liver cirrhosis
select candidates for liver biopsy. However, TE is less 
reliable in patients with BMI > 30, which is common in 
NAFLD patients. In fact, subcutaneous fat increases the 
distance between the probe and the liver and does not 
allow a correct estimate of  liver stiffness[123,140,141]. The 
recent introduction of  the XL probe should allow a more 
accurate study of  liver stiffness in patients with a skin-to-
liver capsule distance > 2.5 cm. A limitation of  the XP 
probe would be a skin to-liver capsule distance > 3.5 cm, 
a thickness corresponding to a BMI > 40[139-144]. Studies 
carried out on fibrosis in NASH have reported different 
cut-off  levels. Wong et al[145], in a study with the highest 
number of  patients so far performed reported a 91.1% 
sensitivity and 75.3% specificity at a cut-off  of  7.9 kPa 
for a F ≥ 3 and a 92% sensitivity and 91% specificity, 
respectively[145] at a cut-off  of  10.3 for F4. 
In patients with cholestatic liver diseases (PBC and 
PSC) higher cut-off  levels than for viral LC have been 
reported (17.3 kPa)[146].
Portal hypertension: Various studies have been performed 
using TE to evaluate its reliability in defining the presence 
of  portal hypertension and esophageal varices. A wide 
range of  cut-off  levels have been reported to date and 
TE cannot therefore be considered reliable in defining 
portal hypertension[117].
Recently, a combination of  liver stiffness and spleen 
diameter (measured using ultrasound) and platelet count 
evaluation was proposed to identify patients with portal 
hypertension[147]. 
Transplant patients: TE has also been proposed in 
evaluating fibrosis progression in patients with post-
transplant recurrent hepatitis C. In fact, an increase in 
stiffness values has been associated to an increase in 
the stage of  liver fibrosis[148]. In the study by Adebajo a 
sensitivity and specificity of  83% for significant fibrosis 
(F ≥ 2) and a sensitivity of  98% and a specificity of  84% 
for cirrhosis (F4), were reported[149].
Assessment of  fibrosis during antiviral therapy: Studies 
performed to date do not give definitive indications on 
its utility, as the reduction in liver stiffness is at least in 
part due to the decrease in necro-inflammation[150-153]. The 
EASL guidelines do not advise TE in the follow-up of  
treated patients[130-135].
 A very recent study by D’Ambrosio raises some 
doubts on the ability of  TE to exclude a diagnosis of  
cirrhosis in patients with SVR[153]. In this study, sensitivity 
for the diagnosis of  cirrhosis in SVR, 61 mo after the end 
of  treatment, using 12 kPa as a cut-off  level, was 61% 
(lower than before therapy) while specificity was 95%. 
The authors reported that after treatment in patients with 
SVR, LC also persisted when fibrosis quantity decreased, 
but a nodular architecture associated with annular fibrosis 
(cirrhosis sign) remained. A non-invasive tool cannot 
estimate this morphometric parameter which is essential 
for the diagnosis of  cirrhosis, as it only calculates the 
quantity of  fibrosis and therefore is of  little use.
TE has been shown to be a useful tool in defining LC 
(F4), although it is less reliable in defining lower degrees 
of  fibrosis[117]. In particular settings, recent international 
guidelines advise it[130,135]. It is easy to use, reproducible 
and well-tolerated by patients. Its disadvantages are that a 
dedicated tool is needed, it is inadequate in patients with 
ascites or tight intercostal spaces, reliability is limited in 
obese and diabetic patients using a standard probe and 
its values are influenced by phenomena such as necro-
inflammation, extra-hepatic cholestasis, venous stasis, etc. 
Acoustic radiation force impulse
ARFI is a new ultrasound technique which estimates 
tissue stiffness by measuring the shear wave velocity 
induced by acoustic radiation, an application of  which is 
Virtual Touch™ which provides: (1) tissue imaging; and 
(2) tissue quantification.
Virtual Touch™ tissue imaging estimates stiffness 
in gray-scale, and therefore gives a qualitative measure. 
Virtual Touch™ tissue quantification gives a quantitative 
measure of  stiffness[115].
The greater the stiffness of  a tissue (expression of  
fibrosis), the higher the speed is. ARFI has the advantage 
of  offering an elastographic measurement given by an 
US machine[115]. The US probe automatically produces a 
brief  acoustic impulse at around 2.6 MHz in a region of  
interest (ROI) of  5 mm × 10 mm in size. Using B-Mode 
US, the operator may position the ROI anywhere within 
the liver, 2-8-cm down the Glisson’s capsule (Figure 3A 
and B). Passing through the tissue the acoustic impulses 
generate shear waves spreading perpendicularly to the 
impulses and the stiffness value is obtained by measuring 
the speed. This technique has been developed by Siemens 
on Acuson S2000 and is also available on the Philips 
iU22 ultrasound system. 
Similarly to FibroScanTM, the patient is examined 
supine with the right arm abducted, and the probe is 
positioned in the right intercostal space (usually the 5th). 
The number of  measurements required reported in the 
literature varies between 6 and 10[154,155].
A greater diagnostic accuracy in stiffness measurement 
has been reported in the right lobe than in the left, above 
all in the deeper areas of  the right lobe (5th segment), 
owing to less manual compression[156]. When used 
together with gray-scale US, which allows a choice of  
the area to be measured, ARFI may also be performed in 
subjects with ascites to assess the stiffness of  focal lesions 
and of  steatosis areas. It may avoid vessels, the gallbladder 
or biliary tree which may influence stiffness values; it may 
allow a thorough study of  the liver by using the various 
types of  US technology (B-Mode, Doppler, CEUS, 
elastography). Measurements have a good inter- and 
intra-observer variability both in healthy subjects and in 
CLD patients[124,157]. However, they have some limitations 
because they are not performed in real time, the ROI 
cannot be modified and the ideal range of  measurements 
to be performed is not yet known[157,158].
As in the case of  TE, there are more ARFI studies 
18140 December 28, 2014|Volume 20|Issue 48|WJG|www.wjgnet.com
Soresi M et al . Diagnosis of liver cirrhosis
on patients with HCV-associated liver disease, although 
more recently studies on NAFLD or HBV-associated 
liver disease have also been carried out[154,156,159-167]. Table 
3 reports the cut-offs and diagnostic reliability for liver 
fibrosis at the various stages according to the METAVIR 
score.
Table 4 reports the results of  two meta-analyses; in 
8 studies Friedrich found that the best cut-offs for the 
diagnosis of  fibrosis were: significant (F ≥ 2), 1.34 m/s; 
severe (F ≥ 3) 1.55 m/s; cirrhosis (F ≥ 4) 1.8 m/s; he 
concluded that ARFI is a good tool for the diagnosis of  
significant fibrosis and excellent for severe fibrosis[166]. 
More recently, Nierhoff  et al[167], analysing a greater 
number of  studies, confirmed the diagnostic reliability 
data for significant and severe fibrosis and cirrhosis with 
similar cut-off  values to those of  the previous meta-
analyses. 
Table 5 reports the sensitivity, specificity and AUROC 
at various cut-offs of  ARFI and TE in the diagnosis of  
fibrosis according to the METAVIR score[160-165,168]. The 
results are not unequivocal: according to some studies 
ARFI and TE have a similar accuracy in the diagnosis 
of  F ≥ 3 and F ≥ 4, and FibroScanTM should be more 
reliable in the earlier stages[162-164], while according to 
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Figure 3  The region of interest of acoustic radiation force impulse speed is positioned in the right lobe of the liver, with an intercostal scan performed 
with the help of ultrasound B-mode (A and B). On the right of the display there is the depth at which the measurement is performed and acoustic radiation force 
impulse (ARFI) speed measurement. In panel A subject with normal ARFI speed value (expressed in m/s). In panel B patient with ARFI speed value (expressed in m/s) 
compatible with liver cirrhosis.
Table 3  Diagnostic reliability acoustic radiation force impulse for liver fibrosis and optimal cut-offs
Ref. Patients analyzed 
by ARFI (n)
Etiology F ≥ 2 F ≥ 3 F = 4
Cut-off 
m/s
Se% Sp% AUROC Cut-off 
m/s





  74 HCV 1.22 100   71 0.91 1.54 97 100 0.99 1.94 100 98 0.99
Friedrich-Rust et al[160]   81 HCV/HBV 1.37   69   92 0.82 1.45 84 86 0.91 1.75   82 91 0.91
Lupsor et al[161] 102 HCV 1.34   68   93 0.86 1.61 79 95 0.91 2.00   80 95 0.94
Yoneda et al[162]   54 NASH 1.77 100 91 0.97 1.91 100 96 0.98
Piscaglia et al[156]   70 Mixed 1.63   59 100 0.79 1.67 75 97 0.91 1.87   81 91 0.91
Rizzo et al[163] 139 HCV 1.31   81   70 0.86 1.71 91 86 0.94 2.11   83 86 0.89
Sporea et al[164] 199 Mixed 1.27   89   68 0.89 1.56 80 89 0.88 1.71   93 87 0.93
Sporea et al[154]   93 Mixed 1.41   71   78 0.77 1.69 73 88 0.79 1.81 100 88 0.92
Sporea et al[165] 911 HCV 1.33   69   80 0.80 1.43 75 81 0.82 1.55   84 76 0.84
Se: Sensitivity; Sp: Specificity; AUROC: Area Under Receiver Operating Characteristic; F: METAVIR fibrosis stage; ARFI: Acoustic radiation force impulse; 
HCV: Hepatitis C virus; HBV: Hepatitis B virus; NASH: Nonalcoholic steatohepatitis. 
Table 4  Results of two meta-analyses on the reliability of acoustic radiation force impulse and optimal cut-offs
Ref. Studies (n) Etiology F ≥ 2 F ≥ 3 F = 4
Cut-off 
m/s










Friedrich-Rust et al[166]   8 Mixed 1.34 79 85 0.872 1.55 86 86 0.912 1.80 92 86 0.932
Nierhoff et al[167] 36 Mixed 1.35 - - 0.841 1.61 - - 0.891 1.87 - - 0.911
1SROC: Area under the Summary Receiver Operating Characteristic; 2AUROC: Area Under Receiver Operating Characteristic. F: METAVIR fibrosis stage.
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others ARFI should have a greater accuracy[163]. In a 
recent meta-analysis comparing ARFI and FibroScanTM, 
Bota reported a similar performance, suggesting that the 
accuracy of  the two tools is similar for the diagnosis of  
severe fibrosis[169]. 
When compared with the FibroScanTM M Probe, 
ARFI had a better reliability in obese patients; however, 
the introduction of  the new XL probe will probably 
reduce this gap. 
ARFI and transaminases: ARFI values are also influenced 
by necro-inflammatory activity, albeit to a lesser extent 
than in TE. In patients with normal ALT, ARFI values 
are significantly lower than in patients with increased 
ALT values[169].
In conclusion, all these studies show that ARFI, as 
well as TE, are able to diagnose severe fibrosis (F ≥ 3) or 
cirrhosis (F ≥ 4) with a higher accuracy, while for lower 
levels of  fibrosis reliability is reduced, due to the data 
overlap. 
 
Portal hypertension: To date, there are no results giving 
precise information on the ability of  this tool to predict 
portal hypertension[170].
Magnetic resonance elastography 
MRE is similar to ultrasound elastography, it uses a 
vibration device to induce a shear wave in the liver. The 
system consists of  an active driver, located outside the 
magnet room, which generates continuous low frequency 
vibrations (60 MHz), lower than TE. These vibrations are 
transmitted to a drum-like passive driver. The trasducer is 
positioned in the right hypochondrium (or last posterior 
ribs). The acoustic vibrations, which then transmits into 
the body, produce shear wave motion within the liver. 
The shear wave propagation within the liver together with 
a modified phase-contrast MR sequence, and processing 
the wave images with an inversion algorithm obtain a 
quantitative image of  shear stiffness (elastogram)[171].
Advantages of  MRE includes: (1) It can be used in 
obese or ascites patients; (2) It is not limited by narrow 
intercostal space; and (3) It has a higher sensitivity than 
the elastographic methods in defining mild fibrosis and it 
has a better reproducibility. 
Recently, Guo et al[172] has reported AUROC for MRE 
staging fibrosis of  0.94, 0.97, 0.96, and 0.97 for F1-F4, 
respectively, whereas AUROC for ARFI staging of  0.82, 
0.85, 0.94, and 0.94 for F1-F4, respectively. Huwart et 
al[173] found that MRE has a better diagnostic accuracy 
than ultrasound elastography for staging liver fibrosis.
In MRE different cut-offs of  cirrhosis have been 
reported. Venkatesh proposes 4.13 kPa as cut-off  for 
LC, while values between 2.84 and 2.93 would be able to 
distinguish a normal liver from a fibrotic one[174].
Moreover, Loomba has reported, in liver steatosis of  
very obese patients (BMI: 50.07 ± 13.4), AUROC values 
for MRE, discriminating advanced fibrosis from mild 
fibrosis, of  0.924; a threshold greater than 3.63 kPa had a 
sensitivity of  0.86, specificity of  0.91, PPV of  0.68, and 
NPV of  0.97[175].
Combining non-invasive methods to diagnose LC
To improve the diagnostic accuracy of  the individual non-
invasive methods described above, recent data from the 
literature have proposed their combined use. For example, 
a recent paper evaluated and compared the ability of  
serum hyaluronic acid and YKL-40 values, as well as TE 
findings, to predict advanced hepatic fibrosis in a cohort 
from a single pediatric center. It concluded that YKL-40 
had no predictive value and TE was superior to HA, but 
the addition of  HA did not improve the performance of  
TE[176]. In another study fibrosis staging and biochemical 
data to calculate APRI, FIB-4, and AST/ALT-ratio (AAR) 
were analyzed. Logistic regression was performed to 
investigate whether biochemical scores were significant 
predictors of  advanced fibrosis independent of  TE. 
The authors concluded that the combination of  TE and 
FIB-4 was useful in the prediction of  advanced fibrosis, 
even if  the effect of  this combination was marginal when 
only asymptomatic patients were included[177].
In 2005, Castéra et al[178] prospectively assessed the 
performance of  FibroScanTM in patients with chronic 
hepatitis C combined with Fibrotest and APRI in 
predicting the stage of  liver fibrosis. The authors found 
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Table 5  Diagnostic reliability between acoustic radiation force impulse and transient elastography and optimal cut-offs
Ref. Etiology Transient elastography ARFI













Friedrich-Rust et al[160] HCV 0.84 0.91     0.910 0.82 1.37 0.91 1.45 0.91 1.75
Lupsor et al[161] HCV 0.96 8.1 0.96 0.6   0.97 13.1 0.86 1.34 0.90 1.61 0.94 2.00
Yoneda et al[162] NASH - - 0.99 9.9     0.998 16.0 0.97 1.77 0.97 1.99
Rizzo et al[163] HCV 0.78 6.5 0.80 8.8 0.8 11.0 0.86 1.3 0.94 1.70 0.89 2.00
Sporea  et al[164] Mixed 0.91   0.99 0.77 1.41 0.79 1.69 0.92 1.81
Sporea et al[165] HCV 0.82 6.7 0.87 9.6   0.93 11.9 0.81 1.36 0.86 1.47   0.885 1.69
Bota et al[168] Mixed  0.871 - - -    0.931 -  0.851 1.31 - -   0.931 1.80
1SROC: Area under the Summary Receiver Operating Characteristic, Meta-analysis. Se: Sensitivity; Sp: Specificity; AUROC: Area Under Receiver Operating 
Characteristic; F: METAVIR fibrosis score; ARFI: Acoustic radiation force impulse; HCV: Hepatitis C virus; NASH: Nonalcoholic steatohepatitis. 
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that the best performance was obtained by combining 
the FibroScanTM and Fibrotest, with areas under the 
ROC curve of  0.88 for F > 2, 0.95 for F > 3, and 0.95 
for F = 4. When the FibroScanTM and Fibrotest results 
agreed, liver biopsy examination confirmed them in 
84% of  cases for F > 2, 95% for F > 3, and 94% for 
F = 4. Their conclusion was that the combined use of  
FibroScanTM and Fibrotest to evaluate liver fibrosis could 
avoid a biopsy procedure in most patients with chronic 
hepatitis C. Previous studies, however, did not find any 
improvement in the accuracy of  predicting cirrhosis 
when TE and other serum markers (in particular platelet 
count and procollagen Ⅲ N-terminal peptide) were 
combined[179]. 
Highlights
Apart from the methods here described, in recent years 
new elastographic methods are emerging for the study 
of  liver fibrosis: the Supersonic Shear Imaging[180], also 
named ShearWave™ elastography, which is based on 
the measurement of  the velocity of  a local shear wave 
through soft tissues and a recently proposed method in 
China, the Fibrotouch®. 
CONCLUSION
During the progression of  CLD evaluating liver 
fibrosis is of  paramount importance. Liver biopsy 
cannot be performed in all patients for the series of  
reasons mentioned above. Consequently, in the last few 
years other non-invasive serological tests and imaging 
techniques have been proposed as reliable indicators of  
fibrosis. 
From the literature data it is evident that no single 
non-invasive test can substitute liver biopsy in any phase 
of  fibrosis progression. However, it can now be affirmed 
that both serological tests and imaging techniques are 
quite reliable for diagnosing LC as well as for excluding 
the presence of  fibrosis. In contrast, in the intermediate 
stages their reliability is limited. 
Sequential flow charts, using serological tests and 
imaging techniques, could be used to help improve 
diagnostic reliability.
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